act-280778
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01264692)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Voltage-gated T-type calcium channelINHIBITOR
Voltage-gated T-type calcium channel inhibitor
- Voltage-gated L-type calcium channelINHIBITOR
Voltage-gated L-type calcium channel inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(OC)c2[nH]c(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CC[C@@H]3C=C4c3ccccc3)nc12- Mol. weight
- 545.72 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068504 ↗
Also known as
- act-280778
- act-280778
- isobutyric acid 2-(2-((3-(4,7-dimethoxy-1h-benzoimidazol-2-yl)propyl)methylamino)ethyl)-5-phenylbicyclo(2.2.2)oct-5-en-2-yl ester
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01264692 | Phase 2 | Feb 1, 2011 | Actelion |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Actelion | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1